Cohance Lifesciences Limited
NSE: COHANCE
About Cohance Lifesciences Limited
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Healthcare · Drug Manufacturers - Specialty & Generic
Results
No scheduled results found for COHANCE.
Historical quarterly results aren't available in the current data feed.
Corporate Actions
No recent corporate actions for COHANCE.
Latest News · Cohance Lifesciences Limited
More in Healthcare
Company overview assembled from NSE results / corporate-action feeds and market news. Not investment advice.

